Literature DB >> 11168441

Increased levels of biochemical markers of bone turnover in relation to persistent immune activation in common variable immunodeficiency.

T Ueland1, S S Frøland, J Bollerslev, P Aukrust.   

Abstract

BACKGROUND: Based on the involvement of cytokines and growth factors in bone homeostasis, we hypothesised that patients with common variable immunodeficiency (CVI), characterised by persistent immune activation in vivo, may have disturbed bone metabolism as evaluated by biochemical markers of bone turnover.
MATERIALS AND METHODS: Serum levels of tumour necrosis factor alpha (TNFalpha), interleukin-6 (IL-6), bone-specific alkaline phosphatase (B-ALP), osteocalcin, carboxyterminal crosslinking telopeptide of type I collagen (CTX-I), insulin-like growth factor (IGF)-I and IGF binding protein-3 (IGFBP-3) were measured in 25 patients with CVI and compared to 25 age- and sex-matched healthy controls.
RESULTS: Patients with CVI had significantly higher serum levels of CTX-I and B-ALP, and significantly lower serum levels of IGF-I and IGFBP-3 compared to controls as shown in cross-sectional, and as for B-ALP and CTX-I, also during longitudinal testing. No differences were observed for osteocalcin between the two groups. The elevated B-ALP and decreased IGF-I and IGFBP-3 levels were most pronounced in a subgroup of CVI patients characterised by persistent activation of proinflammatory cytokines in vivo. Raised B-ALP and decreased IGF-I and IGFBP-3 were also significantly correlated with enhanced IL-6 and TNF-alpha levels in these patients.
CONCLUSIONS: The present study suggests that persistent immune activation in vivo, with raised levels of proinflammatory cytokines, may be related to disturbed bone homeostasis in CVI patients, further supporting an interaction between immune related mediators and bone metabolism in humans.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11168441     DOI: 10.1046/j.1365-2362.2001.00768.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  5 in total

1.  International Consensus Document (ICON): Common Variable Immunodeficiency Disorders.

Authors:  Francisco A Bonilla; Isil Barlan; Helen Chapel; Beatriz T Costa-Carvalho; Charlotte Cunningham-Rundles; M Teresa de la Morena; Francisco J Espinosa-Rosales; Lennart Hammarström; Shigeaki Nonoyama; Isabella Quinti; John M Routes; Mimi L K Tang; Klaus Warnatz
Journal:  J Allergy Clin Immunol Pract       Date:  2015-11-07

Review 2.  The roles of lipid oxidation products and receptor activator of nuclear factor-κB signaling in atherosclerotic calcification.

Authors:  Linda Demer; Yin Tintut
Journal:  Circ Res       Date:  2011-06-10       Impact factor: 17.367

Review 3.  Cytokines in common variable immunodeficiency as signs of immune dysregulation and potential therapeutic targets - a review of the current knowledge.

Authors:  Farnaz Najmi Varzaneh; Bärbel Keller; Susanne Unger; Asghar Aghamohammadi; Klaus Warnatz; Nima Rezaei
Journal:  J Clin Immunol       Date:  2014-05-15       Impact factor: 8.317

4.  Gut Microbiota-Dependent Trimethylamine N-Oxide Associates With Inflammation in Common Variable Immunodeficiency.

Authors:  Magnhild E Macpherson; Johannes R Hov; Thor Ueland; Tuva B Dahl; Martin Kummen; Kari Otterdal; Kristian Holm; Rolf K Berge; Tom E Mollnes; Marius Trøseid; Bente Halvorsen; Pål Aukrust; Børre Fevang; Silje F Jørgensen
Journal:  Front Immunol       Date:  2020-09-16       Impact factor: 7.561

5.  Targeted Proteomics Reveals Inflammatory Pathways that Classify Immune Dysregulation in Common Variable Immunodeficiency.

Authors:  Roos-Marijn Berbers; Julia Drylewicz; Pauline M Ellerbroek; Joris M van Montfrans; Virgil A S H Dalm; P Martin van Hagen; Baerbel Keller; Klaus Warnatz; Annick van de Ven; Jaap M van Laar; Stefan Nierkens; Helen L Leavis
Journal:  J Clin Immunol       Date:  2020-11-15       Impact factor: 8.317

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.